$EBS News

Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement

Emergent BioSolutions Announces Saudi Approval For ACAM2000, Its Smallpox and Mpox Vaccine

Emergent BioSolutions Inc. 2026 Q1 - Results - Earnings Call Presentation

Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript

Emergent BioSolutions (NYSE:EBS) Surges After Q1 Earnings Beat and Raised Profit Outlook

Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript

Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est

Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est

Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate

Emergent BioSolutions Signs ~$34.5M Agreement With Substipharm Biologics Over Drug Substance Production For Its Japanese Encephalitis Vaccine

Emergent BioSolutions Collaborates With B.C. Provincial Health Services Authority To Provide Nasal Spray For Take-Home Naloxone Program

Emergent BioSolutions (EBS) Price Target Decreased by 11.11% to 12.24

Emergent BioSolutions Secures ~$54M Contract To Provide CNJ-016 Vaccinia Immune Globulin Intravenous To U. S. Department of Health And Human Services' Administration For Strategic Preparedness And Response For Smallpox Preparedness; Gets New $6.6M Incremental Orders With Undisclosed Global Federal Partner For ACAM2000

HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $12

Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture

Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 sales guidance below estimates.

Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript

Emergent BioSolutions Inc (NYSE:EBS) Shares Tumble on Weak Q4 Results and Cautious 2026 Outlook

Emergent BioSolutions Inc. 2025 Q4 - Results - Earnings Call Presentation

Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 sales guidance below estimates.